Literature DB >> 19902328

MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers.

L Macarini1, P Milillo, A Cascavilla, G Scalzo, L Stoppino, R Vinci, G Moretti, G Ettorre.   

Abstract

PURPOSE: The authors sought to evaluate the potential of magnetic resonance (MR) imaging with superparamagnetic iron oxide (SPIO) contrast material for identifying, characterising and differentiating dysplastic nodules (DN) and hepatocellular carcinoma (HCC) in the cirrhotic liver by correlating the results with pathological findings on the explanted liver.
MATERIAL AND METHODS: MR imaging was used to study the liver of 400 cirrhotic patients awaiting liver transplantation, 31 of whom were selected to receive a liver. Of these 31 patients, we included in the study 22 patients (mean age 53 years; range 46-57 years) who underwent liver transplantation within 12-24 h after MR examination. Patients were studied with a 1.5-T device, and scans were acquired before and after the administration of paramagnetic contrast material. For every lesion, we recorded signal intensity on unenhanced baseline T1- and T2-weighted images and enhancement pattern after SPIO administration. Histological examination of the entire liver provided the definitive diagnosis of the lesions.
RESULTS: Histological examination identified 59 lesions: 14 HCC, 4 HCC-DN, 39 DN, and 2 cystoadenomas. Among the 14 HCC, three were well differentiated, eight were moderately differentiated and three were poorly differentiated. Of the 39 DN, 28 were low-grade and 11 high-grade lesions. Unenhanced baseline MR imaging correctly identified and characterised 20 lesions, equal to 33.90% of all lesions: 6 HCC, 12 DN and 2 DN with a subfocus of HCC. SPIO-enhanced MR imaging showed greater sensitivity detecting and characterising 45 lesions, equal to 76.27% of all lesions identified at histology: 14 HCC, 27 DN and 4 DN with subfocus of HCC. SPIO administration improved the sensitivity of MR imaging in lesion detection and characterisation by 42.37%. False negative results with SPIO-enhanced MR imaging occurred in 12 DN (31%), which histological examination revealed to be low-grade DN with a diameter <1 cm.
CONCLUSIONS: SPIO-enhanced MR imaging proved to be of value in detecting and characterising lesions in the cirrhotic liver, allowing differentiation of DN from HCC and providing an early diagnosis of neoplastic degeneration of DN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902328     DOI: 10.1007/s11547-009-0464-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  43 in total

Review 1.  MR imaging of cirrhotic nodules.

Authors:  G A Krinsky; V S Lee
Journal:  Abdom Imaging       Date:  2000 Sep-Oct

Review 2.  Intra- and perinodular hemodynamics of hepatocellular carcinoma: CT observation during intra-arterial contrast injection.

Authors:  O Matsui; K Ueda; S Kobayashi; J Sanada; N Terayama; T Gabata; M Minami; Y Kawamori; Y Nakanuma
Journal:  Abdom Imaging       Date:  2002 Mar-Apr

3.  Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma.

Authors:  Janio Szklaruk; Paul M Silverman; Chusilp Charnsangavej
Journal:  AJR Am J Roentgenol       Date:  2003-02       Impact factor: 3.959

Review 4.  Real-time harmonic contrast material-specific US of focal liver lesions.

Authors:  Orlando Catalano; Antonio Nunziata; Roberto Lobianco; Alfredo Siani
Journal:  Radiographics       Date:  2005 Mar-Apr       Impact factor: 5.333

5.  Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.

Authors:  Y Tang; Y Yamashita; A Arakawa; T Namimoto; K Mitsuzaki; Y Abe; K Katahira; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1999-06       Impact factor: 3.959

6.  Management of adenomatous hyperplastic nodules in the cirrhotic liver: US follow-up or percutaneous alcohol ablation?

Authors:  R Lencioni; C Bartolozzi; D Caramella; G Di Coscio
Journal:  Abdom Imaging       Date:  1993

7.  Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Dongil Choi; Seung Hoon Kim; Jae Hoon Lim; Won Jae Lee; Min Ju Kim; Hyo K Lim; Soon Jin Lee
Journal:  AJR Am J Roentgenol       Date:  2005-04       Impact factor: 3.959

8.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

9.  Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT.

Authors:  Bo Kiung Kang; Jae Hoon Lim; Seung Hoon Kim; Dongil Choi; Hyo Keun Lim; Won Jae Lee; Soon Jin Lee
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

10.  Dual contrast magnetic resonance imaging with combined use of positive and negative contrast agent in human hepatocellular carcinoma.

Authors:  Y Suto; Y Shimatani
Journal:  Br J Radiol       Date:  1995-02       Impact factor: 3.039

View more
  3 in total

Review 1.  Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis.

Authors:  You-Wei Li; Zheng-Guang Chen; Ji-Chen Wang; Zong-Ming Zhang
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 2.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

Review 3.  MRI features of hepatocellular carcinoma related to biologic behavior.

Authors:  Eun-Suk Cho; Jin-Young Choi
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.